Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 5/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | DTYMK | P23919 | 2/20 | 0.40 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.39 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.39 |
| ▸ | PARG | Q86W56 | 1/20 | 0.39 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21263944 | 0.96 | FHIT (0.40) | P2RY1P2RY2P2RX1P2RX3P2RX4 | |
| SCHEMBL21263943 | 0.90 | FHIT (0.45) | P2RY1P2RY2P2RX1P2RX3P2RX4 | |
| SCHEMBL24258636 | 0.89 | RNASEL (0.42) | P2RY1P2RY2P2RX1P2RX3P2RX4 | |
| SCHEMBL24444133 | 0.87 | P2RY1 (0.48) | P2RY1P2RY2SRCSMN1; SMN2RNASEL | |
| SCHEMBL24258604 | 0.85 | POLB (0.41) | P2RY1P2RY2SRCSMN1; SMN2DTYMK | |
| SCHEMBL24258614 | 0.83 | POLB (0.49) | P2RY1P2RY2SRCSMN1; SMN2NT5E | |
| SCHEMBL24258615 | 0.81 | RNASEL (0.38) | P2RY1P2RY2SRCSMN1; SMN2DTYMK | |
| SCHEMBL24258653 | 0.81 | NT5E (0.37) | P2RY1P2RY2SRCSMN1; SMN2NT5E | |
| SCHEMBL21263871 | 0.80 | POLB (0.49) | P2RY1P2RY2SRCSMN1; SMN2DTYMK | |
| SCHEMBL24258651 | 0.78 | RNASEL (0.45) | RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519187-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | P2RY1 1124/4885P2RY2 1259/4885P2RX1 1958/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | P2RY1 1124/4885P2RY2 1259/4885P2RX1 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.